Treatment of cervical dystonia

Bibliography

• Steeves TD, Day L, Dykeman J, et al. The prevalence of primary dystonia: a systematic review and meta-analysis. Mov Disord 2012;27:1789-96
   PubMed Web of Science ®Google Scholar
• Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991;41:1088-91
   PubMed Web of Science ®Google Scholar
• Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord 1991;6:119-26
   PubMed Web of Science ®Google Scholar
• Rubio-Agusti I, Parees I, Kojovic M, et al. Tremulous cervical dystonia is likely to be familial: clinical characteristics of a large cohort. Parkinsonism Relat Disord 2013;19:634-8
   Google Scholar
• Bressman SB, Sabatti C, Raymond D, et al. The DYT1 phenotype and guidelines for diagnostic testing. Neurology 2000;54(9):1746-52
   Google Scholar
• Bressman SB. Dystonia update. Clin Neuropharmacol 2000;23:239-51
   PubMed Web of Science ®Google Scholar
• Brashear A, Ambrosius WT, Eckert GJ, Siemers ER. Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov Disord 1998;13(1):158-61
   Google Scholar
• Papapetropoulos S, Tuchman A, Sengun C, et al. Anterocollis: clinical features and treatment options. Med Sci Monit 2008;14:CR427-30
   Google Scholar
• Van ZM. Cervical dystonia (spasmodic torticollis). Some aspects of the natural history. Acta Neurol Belg 1995;95:210-15
   Google Scholar
• Goldman S, Ahlskog JE. Posttraumatic cervical dystonia. Mayo Clin Proc 1993;68:443-8
   Web of Science ®Google Scholar
• Queiroz MA, Chien HF, Sekeff-Sallem FA, Barbosa ER. Physical therapy program for cervical dystonia: a study of 20 cases. Funct Neurol 2012;27:187-92
   PubMed Web of Science ®Google Scholar
• Zetterberg L, Halvorsen K, Farnstrand C, et al. Physiotherapy in cervical dystonia: six experimental single-case studies. Physiother Theory Pract 2008;24:275-90
   PubMedGoogle Scholar
• Ramdharry G. Case report: physiotherapy cuts the dose of botulinum toxin. Physiother Res Int 2006;11:117-22
   PubMedGoogle Scholar
• Jahanshahi M, Sartory G, Marsden CD. EMG biofeedback treatment of torticollis: a controlled outcome study. Biofeedback Self Regul 1991;16:413-48
   PubMedGoogle Scholar
• Smania N, Corato E, Tinazzi M, et al. The effect of two different rehabilitation treatments in cervical dystonia: preliminary results in four patients. Funct Neurol 2003;18:219-25
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Costa J, Coelho M, Sampaio C. The management of cervical dystonia. Expert Opin Pharmacother 2007;8:129-40
   PubMed Web of Science ®Google Scholar
• Adler CH, Kumar R. Pharmacological and surgical options for the treatment of cervical dystonia. Neurology 2000;55:S9-S14
   Google Scholar
• Jankovic J. Treatment of dystonia. Lancet Neurol 2006;5:864-72
   PubMed Web of Science ®Google Scholar
• Brans JW, Lindeboom R, Snoek JW, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996;46:1066-72
   PubMed Web of Science ®Google Scholar
• Scott AB. Development of botulinum toxin therapy. Dermatol Clin 2004;22:131-3, v
   PubMed Web of Science ®Google Scholar
• Scott AB, Magoon EH, McNeer KW, Stager DR. Botulinum treatment of strabismus in children. Trans Am Ophthalmol Soc 1989;87:174-80
   Google Scholar
• Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 1973;12:924-7
   PubMedGoogle Scholar
• Carruthers A, Kane MA, Flynn TC, et al. The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine–a global, evidence-based botulinum toxin consensus education initiative: part I: botulinum toxin in clinical and cosmetic practice. Dermatol Surg 2013;39:493-509
   PubMed Web of Science ®Google Scholar
• Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987;2(4):237-54
   PubMed Web of Science ®Google Scholar
• Sethi KD, Rodriguez R, Olayinka B. Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ 2012;15:419-23
   PubMedGoogle Scholar
• Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994;9:213-17
   PubMed Web of Science ®Google Scholar
• Brashear A, Watts MW, Marchetti A, et al. Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review. Clin Ther 2000;22(12):1516-24
   Google Scholar
• Brashear A, Bergan K, Wojcieszek J, et al. Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord 2000;15:150-3
   PubMed Web of Science ®Google Scholar
• Jankovic J. Blepharospasm and oromandibular-laryngeal-cervical dystonia: a controlled trial of botulinum A toxin therapy. Adv Neurol 1988;50:583-91
   PubMedGoogle Scholar
• Charles D, Brashear A, Hauser RA, et al. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol 2012;35:208-14
   PubMed Web of Science ®Google Scholar
• Greene PE, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord 1993;8:479-83
   PubMed Web of Science ®Google Scholar
• Greene PE, Fahn S. Response to botulinum toxin F in seronegative botulinum toxin A– resistant patients. Mov Disord 1996;11(2):181-4
   PubMed Web of Science ®Google Scholar
• Lew MF, Brashear A, Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology 2000;55:S29-35
   Web of Science ®Google Scholar
• Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999;53:1439-46
   PubMed Web of Science ®Google Scholar
• Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999;53:1431-8
   PubMed Web of Science ®Google Scholar
• Brin MF, Aoki KR. Botulinum toxin type A: pharmacology. In: Mayer NH, Simpson DM, editors. Spasticity: etiology, evaluation, management, and the role of botulinum toxin. WeMove; New York: 2002. p. 110-24
   Google Scholar
• de Paiva A, Poulain B, Lawrence GW, et al. A role for the interchain disulfide or its participating thiols in the internalization of botulinum neurotoxin A revealed by a toxin derivative that binds to ecto-acceptors and inhibits transmitter release intracellularly. J Biol Chem 1993;268(28):20838-44
   Google Scholar
• Schiavo G, Rossetto O, Catsicas S, et al. Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. J Biol Chem 1993;268:23784-7
   PubMed Web of Science ®Google Scholar
• Schiavo G, Shone CC, Rossetto O, et al. Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin. J Biol Chem 1993;268:11516-19
   PubMed Web of Science ®Google Scholar
• de Paiva A, Meunier FA, Molgo J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999;96:3200-5
   PubMed Web of Science ®Google Scholar
• Assessment: the clinical usefulness of botulinum toxin-A in treating neurologic disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1990;40(9):1332-6
   Google Scholar
• Allergan I. Package Insert, BOTOX (Botulinum toxin Type A Purified Neurotoxin Complex). Allergan, Inc; Irvine: 2000. Available from: http://www.allergan.com/assets/pdf/botox_pi.pdf
   Google Scholar
• Myobloc® [package insert]. 2008
   Google Scholar
• Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174949.htm 2009
   Google Scholar
• Ceballos-Baumann AO. Evidence-based medicine in botulinum toxin therapy for cervical dystonia. J Neurol 2001;248(Suppl 1):14-20
   Google Scholar
• Greene P, Kang U, Fahn S, et al. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990;40:1213-18
   PubMed Web of Science ®Google Scholar
• Borodic GE, Mills L, Joseph M. Botulinum A toxin for the treatment of adult-onset spasmodic torticollis. Plast Reconstr Surg 1991;87(2):285-9
   PubMed Web of Science ®Google Scholar
• Jankovic J, Schwartz KS. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology 1993;43(4):834-6
   Google Scholar
• Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 1990;40:277-80
   PubMed Web of Science ®Google Scholar
• Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990;53(8):633-9
   Web of Science ®Google Scholar
• Gelb DJ, Lowenstein DH, Aminoff MJ. Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis. Neurology 1989;39:80-4
   PubMed Web of Science ®Google Scholar
• Gelb DJ, Yoshimura DM, Olney RK, et al. Change in pattern of muscle activity following botulinum toxin injections for torticollis. Ann Neurol 1991;29(4):370-6
   Google Scholar
• Blackie JD, Lees AJ. Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry 1990;53:640-3
   PubMed Web of Science ®Google Scholar
• Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005;20:783-91
   PubMed Web of Science ®Google Scholar
• Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 1998;64:13-17
   PubMed Web of Science ®Google Scholar
• Pappert EJ, Germanson T. Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord 2008;23:510-17
   PubMed Web of Science ®Google Scholar
• Benecke R, Jost WH, Kanovsky P, et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005;64:1949-51
   PubMed Web of Science ®Google Scholar
• Benecke R. Xeomin in the treatment of cervical dystonia. Eur J Neurol 2009;16(Suppl 2):6-10
   Web of Science ®Google Scholar
• Evidente VG, Fernandez HH, LeDoux MS, et al. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin) in cervical dystonia. J Neural Transm 2013; published online; doi:10.1007/s00702-013-1048-3 [doi]
   Google Scholar
• Ford B, Greene P, Louis ED, et al. Use of intrathecal baclofen in the treatment of patients with dystonia. Arch Neurol 1996;53(12):1241-6
   Google Scholar
• Walsh RA, Sidiropoulos C, Lozano AM, et al. Bilateral pallidal stimulation in cervical dystonia: blinded evidence of benefit beyond 5 years. Brain 2013;136:761-9
   Google Scholar
• Yamada K, Hamasaki T, Hasegawa Y, Kuratsu JI. Long disease duration interferes with therapeutic effect of globus pallidus internus pallidal stimulation in primary cervical dystonia. Neuromodulation 2012; published online; doi:10.1111/j.1525-1403.2012.00464.x [doi]
   Google Scholar
• Ferreira JJ, Bhidayasiri R, Colosimo C, et al. Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia. Funct Neurol 2012;27:225-30
   Google Scholar
• Klein C, Ozelius LJ. Dystonia: clinical features, genetics, and treatment. Curr Opin Neurol 2002;15(4):491-7
   Google Scholar
• Fuchs T, Saunders-Pullman R, Masuho I, et al. Mutations in GNAL cause primary torsion dystonia. Nat Genet 2013;45:88-92
   PubMed Web of Science ®Google Scholar
• Simpson DM, Blitzer A, Brashear A, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1699-706
   PubMed Web of Science ®Google Scholar
• Schmidt A, Klein C. The role of genes in causing dystonia. Eur J Neurol 2010;17:65-70
   PubMed Web of Science ®Google Scholar